Actively Recruiting
Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
Led by Medical University of Vienna · Updated on 2025-09-02
20
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Background: Microvascular dysfunction is a hallmark of hypertrophic obstructive cardiomyopathy (HOCM) and can be visualized non-invasively using cardiac magnetic resonance (CMR) perfusion imaging. In parallel, the six-minute walk test (6MWT) is an established clinical tool to assess submaximal exercise capacity in patients with structural heart disease. Despite its widespread use, the relationship between objective changes in myocardial perfusion and functional improvements assessed by the 6MWT remains insufficiently explored in patients with HOCM on optimal medical therapy (OMT). Aim:This study aims to evaluate whether changes in functional capacity, measured by the 6MWT, correlate with changes in myocardial perfusion reserve (MPR) in HOCM patients treated with OMT. Methods: We will include patients diagnosed with obstructive HCM who previously underwent clinically indicated CMR perfusion scans for risk stratification. These patients are regularly followed in the HCM outpatient clinic of the Medical University of Vienna, where standardized 6MWTs are performed in routine care. Approximately one year after the baseline CMR, a follow-up CMR will be conducted to assess changes in perfusion parameters. This second CMR is clinically justified for improved individual risk stratification as recommended by the 2023 ESC Guidelines on Cardiomyopathies. The primary objective is to assess the correlation between the change in the walking distance in the 6MWT and the change in MPR over a one-year interval. Secondary endpoints include changes in myocardial blood flow (MBF) at rest and during pharmacological stress. All assessments will be integrated with clinical, echocardiographic, and laboratory evaluations.
CONDITIONS
Official Title
Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Willingness to provide written informed consent
- Diagnosis of obstructive hypertrophic cardiomyopathy based on ESC 2023 criteria
- Planned cardiac magnetic resonance imaging with myocardial perfusion for clinical reasons
- Receiving guideline-conform optimal medical treatment
- Ability and willingness to undergo follow-up imaging and testing
- Written informed consent
You will not qualify if you...
- Claustrophobia or other contraindications to cardiac magnetic resonance imaging
- Significant coronary artery disease or prior coronary stent implantation or coronary artery bypass surgery
- History of sudden cardiac arrest or sustained ventricular arrhythmia within 12 months before screening
- Glomerular filtration rate less than 30 ml/min/m2
- Significant liver impairment defined as three times the upper limit of normal for liver enzymes, bilirubin, or alkaline phosphatase, or liver cirrhosis
- Known allergy to contrast agents
- Alternative diseases causing hypertrophic cardiomyopathy such as cardiac amyloidosis or Morbus Fabry
- Pregnant women or women with childbearing potential who desire pregnancy
- Breastfeeding women
- Unwillingness to comply with study procedures and protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medical University of Vienna
Vienna, Austria, 2362
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here